1 reports of this reaction
1.3% of all TETRAHYDROZOLINE HCL reports
#20 most reported adverse reaction
CARDIAC FAILURE is the #20 most commonly reported adverse reaction for TETRAHYDROZOLINE HCL, manufactured by Chain Drug Marketing Assoc., Inc.. There are 1 FDA adverse event reports linking TETRAHYDROZOLINE HCL to CARDIAC FAILURE. This represents approximately 1.3% of all 76 adverse event reports for this drug.
Patients taking TETRAHYDROZOLINE HCL who experience cardiac failure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CARDIAC FAILURE is a less commonly reported adverse event for TETRAHYDROZOLINE HCL, but still significant enough to appear in the safety profile.
In addition to cardiac failure, the following adverse reactions have been reported for TETRAHYDROZOLINE HCL:
The following drugs have also been linked to cardiac failure in FDA adverse event reports:
CARDIAC FAILURE has been reported as an adverse event in 1 FDA reports for TETRAHYDROZOLINE HCL. This does not prove causation, but indicates an association observed in post-market surveillance data.
CARDIAC FAILURE accounts for approximately 1.3% of all adverse event reports for TETRAHYDROZOLINE HCL, making it a notable side effect.
If you experience cardiac failure while taking TETRAHYDROZOLINE HCL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.